Hongming Pan

机构：Sir Run Run Shaw Hospital, Qiqihar Medical University · ORCID：0000-0001-5034-3392

发表论文 364 篇 · 总被引 23059 次 · h-index 62

代表论文

• Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation (2025 · Signal Transduction and Targeted Therapy · 被引 20)
• A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors (2025 · Clinical Cancer Research · 被引 15)
• First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study (2025 · Advances in Therapy · 被引 9)
• Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer (2025 · British Journal of Cancer · 被引 2)
• 544 A phase I/II clinical trial of anti-CLDN18.2/PD-L1 recombinant humanized bispecific antibody Q-1802 combined with XELOX chemotherapy in untreated advanced GC/GEJ patients (2025 · Regular and Young Investigator Award Abstracts · 被引 1)
• Evaluating the efficacy of fruquintinib versus regorafenib and trifluridine/tipiracil in treating advanced metastatic colorectal cancer: A match-adjusted indirect comparison. (2025 · Journal of Clinical Oncology · 被引 1)